BRIEF published on 01/22/2025 at 07:35, 1 year 9 months ago Evotec Collaborates with Korean Entities on Novel Lung Disease Treatments Collaboration Grant Evotec Lung Disease Treatment Development
PRESS RELEASE published on 01/22/2025 at 07:30, 1 year 9 months ago Evotec receives grant from Korean Government to develop novel antibody-based treatments for lung diseases Evotec SE receives US$ 4.5m grant from Korean Government to develop first-in-class therapeutic antibodies for lung diseases like asthma and idiopathic pulmonary fibrosis Evotec SE Grant Therapeutic Antibodies Lung Diseases Korean Government
BRIEF published on 12/11/2024 at 07:34, 1 year 10 months ago Evotec SE and Novo Nordisk Launch LAB eN² Projects for Drug Discovery Drug Discovery Evotec SE Novo Nordisk Cardiometabolic Diseases LAB EN²
PRESS RELEASE published on 12/11/2024 at 07:29, 1 year 10 months ago Evotec SE announces first projects for LAB eN² drug discovery accelerator with Novo Nordisk Evotec SE announces selection of first projects for LAB eN² drug discovery accelerator with Novo Nordisk, focusing on cardiometabolic diseases from academic institutions Drug Discovery Evotec SE Novo Nordisk Cardiometabolic Diseases LAB EN²
BRIEF published on 11/29/2024 at 07:36, 1 year 11 months ago Evotec Announces COO Departure and Internal Restructuring Pharmaceuticals Management Change Evotec COO Departure Internal Restructuring
PRESS RELEASE published on 11/29/2024 at 07:31, 1 year 11 months ago Evotec announces change in Management Board Evotec SE announces the departure of Chief Operating Officer Dr Craig Johnstone effective December 31, 2024, with internal distribution of responsibilities. Management praises Johnstone's contribution and commitment Global Operations Chief Operating Officer Evotec SE Management Board Dr Craig Johnstone
BRIEF published on 11/22/2024 at 17:00, 1 year 11 months ago Evotec SE Comments on Withdrawal of Halozyme's Offer Shareholder Value Evotec SE Acquisition Proposal Halozyme Therapeutics Non-binding Offer
PRESS RELEASE published on 11/22/2024 at 16:55, 1 year 11 months ago EQS-Adhoc: Comment on withdrawn non-binding offer Evotec SE acknowledges withdrawal of non-binding offer by Halozyme Therapeutics Inc. for acquisition. Management reiterates confidence in standalone strategy Acquisition Evotec SE Halozyme Therapeutics Inc. Withdrawn Offer Standalone Strategy
BRIEF published on 11/14/2024 at 22:56, 1 year 11 months ago Evotec SE Responds to Interest from Halozyme Evotec SE Takeover Halozyme Therapeutics Expression Of Interest EUR 11 Per Share
PRESS RELEASE published on 11/14/2024 at 22:51, 1 year 11 months ago EQS-Adhoc: Comment on media report Evotec SE receives non-binding expression of interest from Halozyme Therapeutics Inc. for a takeover offer of EUR 11.00 per share Evotec SE Takeover Offer Expression Of Interest Halozyme Therapeutics Inc. EUR 11.00 Per Share
Published on 10/30/2026 at 23:35, 1 day 14 hours ago Prospect Ridge Announces Closing of Critical Metals Flow-through Unit Private Placement
Published on 10/30/2026 at 23:30, 1 day 14 hours ago Revolve Enters into Definitive Agreement to Acquire Three Project, 6 MW Battery Storage Portfolio in Ontario
Published on 10/30/2026 at 19:00, 1 day 19 hours ago Electric Royalties Ltd. Announces Application for Warrant Extension
Published on 10/30/2026 at 15:30, 1 day 22 hours ago Bluejay Diagnostics Announces 1-for-4 Reverse Stock Split
Published on 11/01/2026 at 10:35, 3 hours 33 minutes ago Shenzhen Unveils APEC China 2026 Host-City Theme Song and Music Video
Published on 11/01/2026 at 05:00, 9 hours 8 minutes ago 2026 Yangtze River Culture Festival Opens in Yonglian Village, Zhangjiagang, Jiangsu
Published on 10/31/2026 at 16:35, 21 hours 33 minutes ago SKYWORTH Solar Announces Global Launch of Solavita as a Smart Microgrid Brand
Published on 10/30/2026 at 22:49, 1 day 15 hours ago EQS-Adhoc: STRATEC SELLS LOSS-MAKING BUSINESS, RECOGNIZES IMPAIRMENTS, AND AMENDS GUIDANCE
Published on 10/30/2026 at 23:00, 1 day 15 hours ago BIOPHYTIS REPORTS FIRST- HALF 2026 RESULTS AND PROVIDES AN UPDATE ON ITS STRATEGY
Published on 10/30/2026 at 12:00, 2 days 2 hours ago Capital increase through exercise of subscription rights
